Glioblastoma Breakthrough: Shining a Light on Tumor Cells Beyond MRI Detection
"New research reveals how a fluorescent dye can highlight hidden tumor cells in brain cancer, even when MRI scans appear clear."
Glioblastoma multiforme (GBM) is one of the most aggressive forms of brain cancer. Treating it often involves surgery to remove as much of the tumor as possible. Surgeons use various tools and techniques to guide them, including magnetic resonance imaging (MRI). MRI helps visualize the tumor, but sometimes, cancer cells can hide in plain sight, evading detection by conventional imaging.
A fluorescent substance called 5-aminolevulinic acid (5-ALA) is emerging as a valuable tool in GBM surgery. When administered to patients, 5-ALA causes tumor cells to glow under a special blue light, making them easier to see and remove. This technique has significantly improved the extent of tumor resection, leading to better outcomes for patients.
However, a perplexing phenomenon has been observed during 5-ALA-guided surgery: fluorescence in the walls of the brain's ventricles (fluid-filled spaces) even when MRI scans show no sign of tumor involvement. A new study published in Oncology Reports investigates this unexpected fluorescence, shedding light on the presence of tumor cells beyond the reach of MRI detection.
Standard Care and Its Limits
Glioblastoma is an aggressive and prevalent primary brain tumor in adults. Standard-of-care treatment includes surgery, radiation, and chemotherapy. Despite these approaches, mortality remains high, reflecting challenges such as immune evasion, tumor repopulation by stem cells, and limited drug penetration across the blood-brain barrier. These limitations have contributed to the need for improved therapies.
Unveiling Hidden Tumor Cells with 5-ALA Fluorescence
The study, led by researchers at Yonsei University College of Medicine in South Korea, involved 19 patients with newly diagnosed GBM located near the lateral ventricle. During surgery, the surgeons carefully examined the ventricular walls for fluorescence after administering 5-ALA. They collected tissue samples from areas with and without fluorescence, even if the MRI scans showed no tumor presence.
- Intraoperative Observation: Surgeons used microscopes with special filters to identify areas of fluorescence in the ventricle walls during GBM surgery.
- Tissue Sampling: 25 ventricular wall tissue samples were collected, regardless of whether they showed fluorescence or had visible tumor involvement on MRI.
- Histopathological Analysis: These samples underwent detailed examination to determine if tumor cells were present, and advanced techniques like immunohistochemistry and genetic analysis were used.
Comparing Intraoperative Guidance
A prospective controlled multicenter clinical trial evaluated intraoperative magnetic resonance imaging against 5-aminolevulinic acid guidance during resection of newly diagnosed glioblastoma. The investigators could not confirm that intraoperative MRI was superior to 5-ALA for achieving complete resections. The result suggests that adding intraoperative MRI does not automatically provide a better extent-of-resection outcome than 5-ALA guidance in this setting.
Why More Resection Is Not Everything
Glioblastoma remains difficult to treat partly because the central nervous system has a relatively immune-privileged environment, including a lack of antigen-presenting cells and lymphatics. Surgical evidence also has not established whether further increasing the extent of resection improves progression-free or overall survival. Together, these points show why technical removal of more visible tumor does not by itself resolve the biological and clinical challenges of glioblastoma.
Infiltrative Borders and Fluorescence Limits
Glioblastoma cells can infiltrate adjacent brain tissue in a crab-like pattern and form networks with tumor micro-vessels through ultra-long, thin protrusions. This invasive architecture helps explain why tumor borders can extend beyond an obvious mass. In a meta-analysis, positive 5-ALA fluorescence was reported in 169 of 212 newly diagnosed glioblastomas, or 79.7%, and in 89 of 119 recurrent cases, or 74.8%. These findings indicate both the biological complexity of tumor borders and the imperfect reach of fluorescence-based identification.
Implications and Future Directions for Glioblastoma Treatment
This study highlights the potential of 5-ALA fluorescence to reveal hidden tumor cells that MRI might miss. This could lead to more complete tumor removal during surgery, potentially improving patient outcomes. However, the study also raises questions about what causes fluorescence in the absence of tumor cells. Further research is needed to understand the nature of this unexpected ventricular wall fluorescence and to optimize the use of 5-ALA in GBM surgery. More studies including molecular characterization, of these falsely fluorescing samples are warranted.
A More Precise Disease Definition
The Society for Neuro-Oncology describes glioblastoma as the most common type of malignant primary brain tumor and a major cause of morbidity and mortality. The 2021 World Health Organization classification restricted the glioblastoma designation to isocitrate dehydrogenase-wildtype tumors. Research on the tumor immune environment has also identified bone marrow-derived macrophages within tumor tissues and brain-resident microglia mainly around glioblastoma tissues. These observations support combining precise disease classification with detailed study of the tumor immune ecosystem.
Toward Innovative Therapies
Recent reviews continue to characterize glioblastoma as the most aggressive and lethal brain tumor in adults, with major challenges for patient survival. Current treatments include surgery, chemotherapy, radiation, and immunotherapy. One review reports a five-year survival of only 6.8% and describes glioblastoma as an incurable fatal disease. It identifies innovative strategies, including genetic therapies, as part of the effort to develop more effective treatment.
Beyond the Tumor-Centric Model
A 2026 review argues that glioblastoma research should consider the patient’s systemic body condition alongside the tumor itself. It states that the traditional tumor-centric model can overlook systemic comorbidities that influence disease progression and therapeutic outcomes. The review therefore frames glioblastoma as a disease whose behavior and treatment response may be shaped by interactions between the tumor and broader systemic health.
Rare Long-Term Survivors
Glioblastoma affects about three people per 100,000 each year, and one case report cites a three-year survival rate of about 10%. For patients older than 65, that report gives a three-year survival rate of about 5%. Long-term survival is uncommon, but case reports describe a small percentage of patients who survive for many years, including exceptional cases lasting decades after surgical removal. These cases demonstrate substantial variation in individual outcomes without changing the disease’s generally serious prognosis.